- Ascendis Pharma (NASDAQ:ASND) initiated with Overweight rating and $36 (30% upside) price target by JPMorgan.
- American Renal Associates (NYSE:ARA) upgraded to Outperform by Wells Fargo.
- Albany Molecular Research (NASDAQ:AMRI) downgraded to Equal Weight by Morgan Stanley.
- Mazor Robotics (NASDAQ:MZOR) downgraded to Market Perform by Wells Fargo.
- Omeros (NASDAQ:OMER) downgraded to Neutral with a $15 (8% upside) price target by Cantor Fitzgerald.
- TransEnterix (NYSEMKT:TRXC) downgraded to Neutral with a $0.70 (15% upside) price target by B. Riley.